Minnesota Glomerular Disease Program

Minnesota Glomerular

Front Row from Left to Right: Lama Ghazi, Michelle Hintz, Surabhi Thakar, Charlotte Quinton
Back Row from Left to Right: Rana Leed, Patrick Nachman, Katti Woerner, and Elizabeth Miller

Mission

To provide patients with glomerular disease with expert, individualized care and access to clinical trials.

Covered Diseases

  • Any glomerular disease, including (but not limited to):
    • Focal Segmental Glomerulosclerosis (FSGS)
    • Membranous nephropathy
    • Minimal change disease 
    • IgA nephropathy
    • Immune complex mediated diseases
  • For systemic diseases associated with Systemic Lupus Erythematosus or vasculitis, please visit the Minnesota Multidisciplinary Vasculitis Program webpage

Goals

  • Provide patients with glomerular disease with expert care which is organized, streamlined and efficient.
  • Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
  • Provide patients with access to cutting-edge clinical trials.
  • Facilitate translational research.
  • Provide a venue for health care providers training in the care of patients with glomerular disease.

Our Team

Physicians

  • Patrick H. Nachman, MD
  • Michelle Rheault, MD (pediatric nephrology)
  • Surabhi Thakar, MD
  • Katti Woerner, DO

Clinical & Translational Research Team

  • Lama Ghazi, MD - Data Management
  • Elizabeth Miller, RN, BAN, PHN, CCRC - Study Coordinator
  • Charlotte Quinton, RN, BSN - Study Coordinator
  • Scott Rajala, CCRP - Translational Research Assistant

 

Ongoing Clinical Trials

FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS).

ClinicalTrials.gov
Identifier: NCT03493685

Phase 3 trial

Principal Investigator

Michelle Rheault, MD

Study Coordinator

TBD


A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis(FSGS).

ClinicalTrials.gov
Identifier: NCT03536754

Phase 2

Principal Investigator

Patrick H. Nachman, MD

Study Coordinators

Charlotte Quinton, RN, BSN
quint003@umn.edu

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu


An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome

ClinicalTrials.gov
Identifier: NCT03703908

Phase 2 trial

Principal Investigator

Patrick H. Nachman, MD

Study Coordinators

Charlotte Quinton, RN, BSN
quint003@umn.edu

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu


An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis.

ClinicalTrials.gov
Identifier: NCT03598036

Phase 2

Principal Investigator

Patrick H. Nachman, MD

Study Coordinators

Charlotte Quinton, RN, BSN
quint003@umn.edu

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

IGA NEPHROPATHY

A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd).

ClinicalTrials.gov
Identifier: NCT03643965

Phase 3

Principal Investigator

Surabhi Thakar, MD

Study Coordinators

Charlotte Quinton, RN, BSN
quint003@umn.edu

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu


A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN).

ClinicalTrials.gov
Identifier: NCT03608033

Phase 3

Principal Investigator

Patrick H. Nachman, MD

Study Coordinators

Charlotte Quinton, RN, BSN
quint003@umn.edu

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu